· The OmniaBio delegation visited Korea for two days to collaborate with MEDIPOST’s CDMO business and meet Korean CDMO customers
· MEDIPOST provides a total solution that supports the entire process of new drug development through the introduction of OmniaBio’s world-class CDMO
MEDIPOST (CEO Wonil Oh) announced on December 1st that OmniaBio, the affiliate specializing in CDMO of cell gene therapy, had visited Korea to discuss plans to collaborate with MEDIPOST’s CDMO business. CEO Mitchel Sivilotti of OmniaBio and CEO Michael May of CCRM, OmniaBio’s parent company, also participated in this visit.
The visit lasted for two days, from November 30th to December 1st, with a visit to the CDMO facility and CARTISTEM® production site at the MEDIPOST GMP plant and met with Korean CDMO customers.
OmniaBio visited the CDMO site in MEDIPOST’s Guro GMP plant and toured the site of the cell and gene therapy consignment production facility and spoke with research personnel. At the site, the two companies discussed ways to work togetherin collaboration for the CDMO project connecting North America and East Asia.OmniaBio explorer to provide provide its process development (PD) capabilities and knowledge, such as its quality management systems.
CEO Mitchel Sivilottiof OmniaBio said, “this visit was a good opportunity to check the quality of MEDIPOST’s CDMO facilities and manpower. We expect to serve as a bridge for OmniaBio’s advancement into Asia by utilizing MEDIPOST’s CDMO facilities and CARTISTEM’s entire development know-how.
An official from MEDIPOST said, “we have decided to collaborate with OmniaBio’s CDMO business that has followed global standards for a long time, to advance into the Korean CDMO business”, and also said, “We plan to provide a total solution by combining our 20 years of cell and gene therapy development and production capabilities with OmniaBio’s differentiated process development, production, and quality control system to create a one-stop solution that supports the entire process of drug development, from product development to clinical trials and commercialization.”
Meanwhile, MEDIPOST, which announced its entry into the CDMO business for a new future growth engine, not only acquired a stake of OmniaBio of Canada, but also built the latest sterilized production facilities exclusively for CDMO branches in the Korean GMP this past October and began actively taking orders.
